November 28, 2013: BioAegis Therapeutics Completes Engineering Run of High-Yield Recombinant Plasma Gelsolin

Company to enter Full-Scale cGMP Production for Clinical Trials

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – March 4, 2013) BioAegis Therapeutics announced today it has completed its engineering manufacturing run and is preparing to launch its manufacture of clinical supplies. The campaign to produce recombinant protein in E. coli was successful and generated higher than expected yields. Plasma gelsolin has also been discovered to be an important component of innate immunity that boosts the body’s response to pathogens. Repletion in numerous animal models has been shown to safely prevent morbidity and mortality.